Demodex Blepharitis Disease

Published Date : Aug 2023
Category : Environmental Diseases
Delivery Timeline : 48 hrs
Buy NowOrder by POGet a quote
Login To Access

The Service Architecture for Demodex Blepharitis

Fighting the Demodex Blepharitis (DB): Generating Health Benefits by Exploring the Industry Insights”

Eyes are the windows to opportunity, vision, and achievement in the chaotic world of business and growth. However, small, elusive animals known as Demodex mites are silently causing the widespread pandemic of Demodex blepharitis by hiding in the shadows of these windows. Millions of people are affected by this widely undiagnosed ailment, which influences their comfort, productivity, and general well-being.

Demodex blepharitis is a common inflammatory eye condition involving the skin, eyelashes, lash follicles, and sebaceous glands that are often overlooked. Demodex mite infestation, an ectoparasite typically seen on human skin, is associated with the disease. Both symptomatic and asymptomatic individuals harbour the Demodex mite species D folliculorum and D brevis in their eyes.

Demodex Folliculorum Blepharitis refers to an infestation of eyelashes and follicles by D. folliculorum clusters to the root of the lashes. Whereas Demodex Brevis Blepharitis involves infestation of the Meibomian gland preferentially by D. brevis.

Figure- Demodex mites in rosacea (~source: National Rosacea Society)

Demodex mites appear in 30 to 90% of blepharitis patients. The normal incidence rate of mite infection is between 13 and 70% worldwide. According to NCBI, in 2022, the total patient population exhibiting symptoms of DB was divided into groups. Firstly, it was discovered that 1.2 million people had dry eyes and were currently taking a prescription medication to treat it; secondly, 2.3 million people had contact lens sensitivity; and lastly 2.2 million people that had cataracts. 

Additionally, the prevalence of Demodex blepharitis in community populations has been reported by NIH ranging from 41 to 70% in the world. Demodex infestation rises with age, prevalence is 13% for the age group of 3 –15 years, 68% for the age group of 16 –60 years, 84% for the age group of 60–70 years, and 96% for the people above 70 years.

A survey of ophthalmologists and optometrists in the United States found that between 37 and 47% of the patients have examined or experienced blepharitis symptoms. Furthermore, an asymptomatic and symptomatic Meibomian gland impairment caused by blepharitis was reported in 21.9% and 8.6% of participants in a recent cross-sectional investigation in Spain on a randomly chosen sample population, respectively. There were no known studies measuring Demodex blepharitis in commercial insurance, Medicare, or Medicaid databases, based on a search of MEDLINE, PubMed, EBSCO, Cochrane, PROQUEST, and Google Scholar in June 2022.

Although several oral, topical, eyelid hygiene, and device-based options have been used clinically and evaluated in studies for the management of Demodex blepharitis, none have been FDA-approved to treat the disease. Thus, a robust study is required to accurately assess the prevalence of Demodex blepharitis in various patient populations.

The healthcare sector must give priority to research initiatives and make significant investments in extensive research to fill the information gap and to gain precise estimation and prevention of Demodex blepharitis in various patient demographics. To better understand this medical condition and develop focused diagnostics and therapies, ophthalmologists, optometrists, and research organizations should collaborate with DLI. There are tremendous market expansion prospects for advanced therapeutics and diagnostics as awareness of Demodex blepharitis rises. Businesses that create effective, non-invasive procedures for diagnosing Demodex blepharitis early will gain a competitive advantage.

Symptoms of Demodex blepharitis:

According to Optometrists Network, symptoms of Demodex blepharitis are:

  • Dry eyes
  • Redness
  • Tearing
  • Eye twitching
  • White flakes in eyelashes
  • Burning or stinging
  • Eye or eyelid irritation
  • Itchy eyes or eyelids
  • Foreign body sensation
  • Intermittent blurred vision
  • Light sensitivity
  • Brittle/loss of eyelashes
  • Misdirected eyelashes
  • Eye or eyelid infections

Demodex mites also cause:

  • Chalazion
  • Meibomian Gland Dysfunction
  • Ocular Rosacea
  • Styes

With the Advanced DiseaseLandscape Insights Services, Surpass the Competition While Redefining Demodex Blepharitis Diagnostic Analysis

Diagnostic Techniques: Demodex Blepharitis

  1. Eyelid Examination:

Eye doctors perform a comprehensive examination of the eyelids using a slit lamp microscope. They will look for signs of inflammation, redness, and crusting on the eyelid margins, which are indicative of Demodex blepharitis.

  1. Epilation and Microscopic Examination:

Eyelashes are plucked (epilated) from the eyelid margins and then examined under a microscope. The presence of Demodex mites, eggs, or waste material on the eyelashes confirms the diagnosis.

  1. Meibomian Gland Expression:

The meibomian glands are located in the eyelids which get affected by Demodex infestations. Expression of these glands reveals the presence of mites and associated inflammation.

  1. In vivo Confocal Microscopy (IVCM):

This non-invasive imaging technique allows for high-resolution examination of the skin and hair follicles. IVCM provides detailed images of Demodex mites and other relevant structures.

  1. Demodex Quantification Tests:

Some specialized tests involve counting the number of Demodex mites per eyelash or measuring their density on the eyelid margins.

  1. Eyelash Cellophane Tape Test:

A piece of cellophane tape is pressed against the eyelids and then removed to pick up mites or debris, which is then visualized under a microscope.

  1. Fluorescein Staining:

Fluorescein dye should be used to highlight any damage or abnormalities on the surface of the eye, which is caused by Demodex blepharitis.

  1. Patient History and Symptoms:

Gathering information about the patient's history and symptoms, such as itching, redness, irritation, and crusty eyelids helps in the diagnosis of Demodex blepharitis.

Stay Ahead of the Competition and Unlock New Horizons of the Diagnostic Industry with DiseaseLandscape Insights Services and Create a Healthier Future for the Healthcare Organization

The Market Competitors who are Transforming Healthcare with Their Innovative Diagnostic Inventions are Listed Below:

Diagnostic Market Players

Eyelid Examination


Epilation and Microscopic Examination

In vivo Confocal Microscopy (IVCM)

TearScience Inc.

Haag-Streit AG

Heidelberg Engineering

Optovue Inc.

Enova Illumination

Haag-Streit AG

Heidelberg Engineering Inc.


Optovue Inc.

Tomey Corporation


Carl Zeiss Meditec AG

Konan Medical USA Inc.

Topcon Corporation

Huvitz Co., Ltd.

Keeler Ltd.

Carl Zeiss Meditec AG

Leica Microsystems (Danaher Corporation)

Topcon Medical Systems, Inc.

Eagle Vision

Bioptigen, Inc. (Acquired by Leica)

Haag-Streit USA

DGH Technology, Inc.

Massa Co., Ltd.

Reichert Technologies (a unit of AMETEK, Inc.)

Oculus, Inc.

Konan Medical


Keeler Ltd.

Ziemer Ophthalmic Systems


Diagnostic Products

Eyelid Examination


Epilation and Microscopic Examination

In vivo Confocal Microscopy (IVCM)


TOMEY BlephEx® Epilator


LipiView® II Ocular Surface Interferometer

BlephEx® Epilator

Smart RCM

RTVue® XR Avanti with AngioVue®

Eyepeace® Eyelid Epilator


PSL Portable Slit Lamp with Imaging Module

Demodex+® Epilation Device

RTVue XR Avanti


The CA-800 Corneal Analyze

Envisu R430

Tono-Pen® XL Applanation Tonometer



The EyeKinetix pupillometer

Keratograph® 5M

AXIS Image Management and Analysis System

TearLab® Osmolarity System

Keeler TearCheck™ Meibomian Gland and Demodex Evaluator

CellChek® D+ CEM System


EagleVision ProEpilator™

iVue® SD-OCT with Corneal Adapter

Treatment Techniques: Demodex Blepharitis

Experience Healthcare Revolution through Innovative Approaches of DiseaseLandscape Insights Services and Optimize Treatment Techniques Based on Comprehensive Market Research

Treatment typically aims to control the mite population and alleviate symptoms. Here are the different treatment techniques commonly used to treat Demodex blepharitis:

  1. Eyelid Hygiene:

Regular eyelid hygiene is essential to remove debris, crusts, and excess oil that harbour Demodex mites. This includes warm compresses to loosen debris and then gently cleansing the eyelids with diluted baby shampoo or commercial lid scrubs. It is essential to avoid harsh soaps or cleansers that result in irritation of the eyes.

  1. Tea Tree Oil:

Tea tree oil has natural antiparasitic properties and is commonly used to treat Demodex infestations. It is in a diluted form, such as tea tree oil-based lid wipes or cleansers, to the eyelids to help eliminate the mites.

Terpinen-4-ol (T40), the most active component of tea tree oil, has been isolated by scientists and used to treat Demodex. Cliradex company’s (Bio-Tissue, Natural Eyelid, Eyelash, and Facial Cleansing Towelettes), which contains a high concentration of T40, has been shown to effectively kill adult mites within 40 minutes of exposure.

  1. Medicated Shampoos:

Some medicated shampoos contain tea tree oil or other antiparasitic agents that are used to wash the scalp and eyebrows, as the mites also infest in these areas.

  1. Topical Antibiotics:

In cases of significant inflammation, doctors prescribe topical antibiotics or steroid creams to reduce inflammation and control secondary bacterial infections.

According to NCBI 2022 Study report, topical Ivermectin 1% cream has been found to be a highly effective treatment modality for Ocular Demodicosis.

  1. Oral Medications:

In severe cases, oral medications such as ivermectin are prescribed to address widespread infestations. These medications work systemically to eliminate mites.

According to Mayo Clinic, Demodex mite rosacea is treated by an oral antibiotic such as doxycycline (Oracea, others) for moderate to severe rosacea with bumps and pimples. If a patient is diagnosed with severe rosacea that does not respond to other therapies, then it is treated with isotretinoin (Amnesteem, Claravis, others).

  1. Artificial Tears:

Lubricating eye drops, or artificial tears are helpful to relieve dry eye symptoms associated with Demodex blepharitis.

  1. BlephEx Treatment:

BlephEx is a procedure performed by an eye care professional to mechanically remove the debris and biofilm from the eyelids and eyelashes. It helps to reduce the Demodex mite population and improve the overall health of the eyelids.

  1. Intense Pulsed Light (IPL) Therapy:

IPL therapy has shown some promise in treating Demodex infestations by destroying mites and reducing inflammation.

  1. Complementary Therapies:

Some natural remedies, such as aloe vera gel or diluted baby shampoo scrubs, are used in conjunction with conventional treatments to soothe the eyelids and reduce inflammation.

DiseaseLandscape Insights Services are Well Equipped with Thorough Analysis of Treatment Options, Service Contributions, Product Portfolios, and Market Players Which Enables to make Informed Decisions and Excel in The Healthcare Sector

Treatment Market Players

Eyelid Hygiene

Tea tree Oil


Théa Pharmaceuticals

NovaBay Pharmaceuticals, Inc.

Pfizer Inc.

Scope Ophthalmics Ltd.


Novartis International AG

Novartis AG


GlaxoSmithKline plc (GSK)



Johnson & Johnson


GDRx EyeBag

Roche Holding AG

Bruder Healthcare

Eye Eco, Inc.

Merck & Co., Inc.

Similasan Corporation






Avenova by NovaBay Pharmaceuticals


Bayer AG



Eli Lilly and Company



Gilead Sciences, Inc.



AbbVie Inc.



Bristol Myers Squibb Company


Treatment Products

Eyelid Hygiene

Tea tree Oil





Lid Scrub®®


TheraTears® Dry Eye Therapy line

Lid Scrub® PLUS


Cliradex® wipes


BlepharaClear 200mg Tablets


Blephadex Eyelid Foam Cleanser

DemodexStat 250mg Tablets



DermaMite 100mg Capsules



Jakafi® (ruxolitinib)







Regulatory framework:

"DiseaseLandscape Insight Services equip businesses with regulatory guidelines that act as a growth catalyst, propelling businesses to success. By adhering to these crucial guidelines, companies can confidently navigate the market, ensuring compliance with the recent updates in regulatory guidelines and building trust with customers. So, unlock hidden opportunities and gain a competitive edge by using effectively the expert DiseaseLandscape insights, empowering the business to flourish in the ever evolving demodex blepharitis market."

Thus, in accordance with the U.S. Food and Drug Administration (FDA) on July 25, 2023, XDEMVYTM (lotilaner ophthalmic solution) 0.25% was approved for the treatment of Demodex blepharitis, as announced by Tarsus Pharmaceuticals, Inc., whose mission is to work on unmet medical needs and apply tried-and-true science and modern technology to revolutionize patient treatment, starting with eye care. The only FDA-approved medication that specifically targets Demodex mites, the underlying cause of Demodex blepharitis, is XDEMVY, formerly known as TP-03.

According to the FDA's 2019 guidelines, participants in clinical trials must meet certain sign and symptom assessments. Participants are disqualified when they met any of the following criteria: advanced conjunctivochalasis, Salzmann's nodular degeneration, asthenopia-related conditions, lid margin disorders (including staphylococcal, demodex, or seborrheic blepharitis; meibomian gland disease; excessive lid laxity; floppy eyelid syndrome; ectropion, entropion), meibomian gland disease, excessive lid etc.

Clinical Trial Assessment:

As a Pharmaceutical Sector Collaborator, DiseaseLandscape Insight Services Offer Comprehensive Assistance for Planning, Conducting, and Evaluating Clinical Studies Focused on The Development of Innovative New Drugs

Below table contains the most recent clinical trials, including their study start date, title, study condition, and respective stages.

Phase I

Phase II

Title: Treatment of Ocular Demodex Infestation with Topical Ivermectin Cream 1%

Condition: The Focus of the Study is to Assess the Effectiveness of Topical Ivermectin in Eliminating Eyelash Sleeves

Title: Pilot Study Comparing the Safety and Efficacy of Two Dosing Regimens of TP-03 for the Treatment of MGD

Condition: Meibomian Gland Dysfunction, Blepharitis & Demodex Infestation

Why DLI?

Recognizing the significance of DiseaseLandscape Insights services, particularly in the fight against demodex blepharitis, is paramount. Our all-encompassing services are tailored to assist the healthcare sector, its professionals, researchers, and industry stakeholders in improving patient outcomes and facilitating business growth and advancement.

By leveraging the potential of extensive market research, our offerings provide invaluable knowledge about the most recent breakthroughs, treatment methodologies, and emerging patterns in Demodex blepharitis management. Armed with these insights, healthcare professionals gain the ability to make informed choices, devise focused strategies, and deliver personalized care to their patients. Additionally, our DiseaseLandscape services serve as a driving force for collaboration and innovation, fostering partnerships among industry stakeholders and researchers to propel advancements in Demodex blepharitis treatment and prevention.

Through harnessing our expertise, healthcare organizations will be able to gain a competitive advantage in the market, enhance patient outcomes, and actively contribute to elevating global healthcare standards.

Vishal SawantBusiness Development

How we can help?

  • 1-888-853-7040 - U.S. (TOLL FREE)
  • +44-1173181773 - U.K. OFFICE
  • +91-7447409162 - INDIA OFFICE
1Chat With UsBook AppointmentBook 15 min Free Analyst Call
We are always looking to hire talented individuals with equal and extraordinary proportions of industry expertise, problem solving ability and inclination interested? please email us
  • FAQ
Disease Landscape Insights LLP
6th Floor, Sr No.207, Office A H 6070 Phase 1, Solitaire Business Hub, Viman Nagar, Pune, Maharashtra, 411014
1-888-853-7040 - U.S. (TOLL FREE)+44-1173181773 - U.K. OFFICE+91-7447409162 - INDIA OFFICE
© Copyright 2024-25 Disease Landscape Insights LLP. All Rights Reserved | Designed by Disease Landscape